European Union watchdog puts sickle cell disease drug on ice
European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use immediately.
Fulcrum Therapeutics Shares Rise 26% on Sickle Cell Disease Market Opportunity
Shares of Fulcrum Therapeutics jumped after Pfizer said it is withdrawing all lots of its sickle cell disease drug Oxbryta and the European Medicines Agency recommended to suspend its marketing authorization.
Pfizer Withdraws Sickle Cell Disease Therapy Oxbryta From Market
Pfizer PFE announced that it is voluntarily withdrawing all lots of its sickle-cell disease (SCD) medication Oxbryta (voxelotor) from all markets where the drug is approved. Why PFE is Withdrawing the Drug All of a Sudden?
Pfizer pulls all lots of sickle cell disease drug from market
Pfizer has announced the withdrawal of all lots of Oxbryta, its drug for sickle cell disease, amid concerns about increased complications and fatal events. The decision, effective immediately in all approved markets,
Pfizer withdraws sickle cell disease treatment from all markets
The decision is based on the totality of clinical data, which now indicates that the benefit of Oxbryta no longer outweighs the risks associated with its use, Pfizer said. Pfizer said it will further review and investigate the available data and had notified regulatory authorities about its findings.
EU disease prevention agency's new chief seeks better public engagement
New chief Pamela Rendi-Wagner says European Centre for Disease Prevention and Control (ECDC) should do more to combat ...
Henlius and Intas receive Positive CHMP Opinion for HETRONIFLY® (approved as HANSIZHUANG in China) in European markets as First-Line Treatment for adult pati…
HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...
EURACTIV3d
Pharma package improvements are needed, says Belgian medicines agency
The Belgian medicines agency, an important stakeholder in the revision of the European pharmaceutical legislation, is ...
PharmiWeb5h
Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
Regulatory Approval/MiscellaneousFormycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases 27.09.2024 / 09:00 ...
PipelineReview.com1d
Duke Street Bio Granted Approval by European Medicines Agency to Launch Next-Generation PARP1-Selective Inhibitor Trial
LONDON, UK I4, 2024 I Duke Street Bio Ltd, a precision medicine biotech developing next generation small molecule cancer therapies, is pleased to ...
Politico Europe3d
Only bold reform will expand access to innovative medicines in the UK
Greater collaboration between industry, government, policymakers and the NHS will be critical for treatment options in the UK ...
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for an update of Novo Nordisk A/S’ (NYSE ...
The Pharma Letter6d
Latest batch of EMA’s human medicines committee recommendations
Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...
Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...
European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand Eczema (CHE)
European Commission Approves LEO Pharma’s Anzupgo® (delgocitinib) Cream for Adults with Moderate to Severe Chronic Hand ...
Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.